RxDoctor Payments Data

Hussain Ibrahim, MD

Interventional Cardiology · West Plains, MONPI 1841622008

Payments from drug & device makers

$2,441in general payments, 2019–2025

Across 51 payments — averaging $47.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$862
  • Medtronic$535
  • Abbott$304
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$158
  • Amgen$112
  • AstraZeneca$108
  • plus $363 from 12 others

What the payments were for

  • Travel & lodging$83334%
  • Food & beverage$1,60866%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,441 in reported general payments places this provider in the 15th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$185,138
Medicare patients
1,428
Services billed
4,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban241$265,058
XareltoRivaroxaban88$108,737
EntrestoSacubitril/Valsartan55$60,510
Repatha SureclickEvolocumab60$34,876
BrilintaTicagrelor22$17,718
Ranolazine ErRanolazine52$4,654
ClopidogrelClopidogrel Bisulfate484$4,204
Amiodarone Hcl127$3,215
Metoprolol Succinate269$2,996
Potassium Chloride162$2,530
Metoprolol Tartrate502$2,500
Digoxin43$2,449
Atorvastatin Calcium363$2,135
Isosorbide Mononitrate ErIsosorbide Mononitrate251$2,089
Diltiazem 24hr Er (Cd)Diltiazem Hcl60$2,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$77$108,73788 claims
NovartisEntresto$19$60,51055 claims
AstraZenecaBrilinta$108$17,71822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in West Plains

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →